Skip to main content

CORRECTION article

Front. Oncol., 14 July 2020
Sec. Molecular and Cellular Oncology

Corrigendum: RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer

\nShiming Tan&#x;Shiming Tan1Pin Yi,&#x;Pin Yi1,2Heran Wang,Heran Wang1,3Longzheng XiaLongzheng Xia1Yaqian HanYaqian Han1Hui WangHui Wang1Biao ZengBiao Zeng1Lu Tang,Lu Tang1,2Qing Pan,Qing Pan1,2Yutong Tian,Yutong Tian1,2Shan RaoShan Rao1Linda OyangLinda Oyang1Jiaxin LiangJiaxin Liang1Jinguan LinJinguan Lin1Min SuMin Su1Yingrui ShiYingrui Shi1Qianjin Liao
Qianjin Liao1*Yujuan Zhou
Yujuan Zhou1*
  • 1Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
  • 2Hunan Cancer Hospital, University of South China, Hengyang, China
  • 3Hepatology Unit, Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou, China

A Corrigendum on
RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer

by Tan, S., Yi, P., Wang, H., Xia, L., Han, Y., Wang, H., et al. (2020). Front. Oncol. 10:649. doi: 10.3389/fonc.2020.00649

The authors regret that there was an error in Figure 6 due to incorrect image editing in Figure 6C. The correct Figure 6 appears below.

FIGURE 6
www.frontiersin.org

FIGURE 6. The effects of RAC1 expression in radiotherapy in vivo. (A) Representative photo of residual tumor of after 3*5 Gy dose of irradiation. (B) The time course of growth of Vector, RAC1, sh-control and sh-RAC1 xenograft tumors with or without IR treatment. (C) IHC staining showed an elevated Ki67 expression and upregulation of RAC1 in RAC1 overexpression xenograft tumor, which represents the radioresistant process in RAC1 overexpressing cells in vivo. Right panel showed a decreased Ki67 expression and downregulation of RAC1 in silencing RAC1 xenograft tumor, which represents the radiosensitivity process in sh-RAC1 cells in vivo. Down panel showed the quantification of scoring of immunostaining in RAC1 overexpression/silencing xenograft. Scale bar 100 μm. Data are expressed as the mean ± SD of different groups of cells from three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: RAC1, lung cancer, radioresistance, epithelial-to-mesenchymal transition, metastasis

Citation: Tan S, Yi P, Wang H, Xia L, Han Y, Wang H, Zeng B, Tang L, Pan Q, Tian Y, Rao S, Oyang L, Liang J, Lin J, Su M, Shi Y, Liao Q and Zhou Y (2020) Corrigendum: RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer. Front. Oncol. 10:1106. doi: 10.3389/fonc.2020.01106

Received: 26 May 2020; Accepted: 02 June 2020;
Published: 14 July 2020.

Edited and reviewed by: Boris Zhivotovsky, Karolinska Institutet (KI), Sweden

Copyright © 2020 Tan, Yi, Wang, Xia, Han, Wang, Zeng, Tang, Pan, Tian, Rao, Oyang, Liang, Lin, Su, Shi, Liao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qianjin Liao, march-on@126.com; Yujuan Zhou, yujany_zhou@163.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.